Annette Hänel

Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)

Roswitha Forstpointner, Michael Unterhalt, Martin Dreyling et al. · Blood · 2006 · 464 citations · Full text

Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma

Ralph Naumann, Bettina Beuthien‐Baumann, Jan Schulze et al. · British Journal of Cancer · 2004 · 170 citations · Full text

Single <i>versus</i> tandem high‐dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long‐term results from the phase <scp>III GMMG</scp>‐<scp>HD</scp>2 trial

K. Elias, Axel Benner, Uta Bertsch et al. · British Journal of Haematology · 2016 · 66 citations · Full text

Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase

Mohamad Jawhar, Nicole Naumann, Juliana Schwaab et al. · Annals of Hematology · 2017 · 58 citations

Hematological Malignancy, Lymphoid Neoplasia, Myeloid/lymphoid Neoplasms +10

Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma

Mathias Hänel, Nicolaus Kröger, S. Sonnenberg et al. · Annals of Hematology · 2002 · 44 citations

Lymphoid Neoplasia, Oncology, Medicine +6